| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Basic Study |
| Article Title |
Liraglutide alleviates diabetic cardiomyopathy in streptozotocin-induced diabetic rats by enhancing mitophagy mediated by the AMPK-Parkin signaling pathway
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ya-Xin Zhu, Wei Zhang, Hui-Lin Qu, Yue Zhang, Ruo-Qian Zhou, Ping Li, Fang Wang, Yan Zhang, Hui-Hui Liu, Sha Li, Qian Dong, Ke-Fei Dou, Yuan-Lin Guo, Jian-Jun Li and Rui-Xia Xu |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81370221 |
| National Natural Science Foundation of China |
82172334 |
| PUMC Youth Fund |
3332018200 |
| National Science and Technology Major Project of the Ministry of Science and Technology of China |
2024ZD0522005 |
| CAMS Innovation Fund for Medical Science |
2016-CXGC05-4 |
| CAMS Innovation Fund for Medical Science |
2021-I2M-1-008 |
|
| Corresponding Author |
Rui-Xia Xu, Cardiometabolic Medicine Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Xicheng District, Beijing 100037, China. ruixiaxu@sina.com |
| Key Words |
Diabetic cardiomyopathy; Liraglutide; Apoptosis; Mitochondria; Mitophagy; Parkin; AMPK signaling pathway |
| Core Tip |
This study investigates the cardioprotective effects of liraglutide, a glucagon-like peptide-1 receptor agonist, in a rat model of diabetic cardiomyopathy (DCM) and in neonatal rat cardiomyocytes exposed to high glucose and palmitate. Liraglutide significantly improved cardiac function, alleviated cardiac damage—reducing myocardial apoptosis, hypertrophy, and interstitial fibrosis, and inhibited cardiomyocyte apoptosis by restoring mitochondrial function and promoting mitophagy through activation of the AMPK-Parkin signaling pathway. These findings provide insight into the role of liraglutide in DCM and support its potential as a therapeutic strategy to mitigate cardiac injury in DCM. |
| Publish Date |
2025-12-15 09:46 |
| Citation |
Zhu YX, Zhang W, Qu HL, Zhang Y, Zhou RQ, Li P, Wang F, Zhang Y, Liu HH, Li S, Dong Q, Dou KF, Guo YL, Li JJ, Xu RX. Liraglutide alleviates diabetic cardiomyopathy in streptozotocin-induced diabetic rats by enhancing mitophagy mediated by the AMPK-Parkin signaling pathway. World J Diabetes 2025; 16(12): 112423 |
| URL |
https://www.wjgnet.com/1948-9358/full/v16/i12/112423.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v16.i12.112423 |
